Announced Wed, 7 Jan · 13:55 IST

Certificate under Regulation 74(5) of SEBI ( Depositories and Participants ) for the quarter ended December 31, 2025.

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Shukra Pharmaceuticals has submitted a routine compliance certificate under SEBI's Regulation 74(5) for the quarter ended December 31, 2025. The certificate was issued by the company's Registrar and Transfer Agent, Purva Sharegistry (India) Pvt. Ltd., confirming that securities received from depository participants for dematerialization were duly processed. The attached details show NIL activity during the quarter from October 1, 2025 to December 31, 2025 — meaning no share certificates were dematerialized in this period. This is a standard quarterly procedural submission required of all listed companies.

Likely market impact

No material impact on shareholders or stock price. This is a routine regulatory compliance filing with no new corporate, financial, or strategic information disclosed.